Thailand and Vietnam have surpassed Singapore as the top crypto trading centers among the ten members of the Association of Southeast Asian Nations (ASEAN).
The 2022 “The Glory of the Centennial NTNU, a century of Taiwanese Design History” Exhibition has officially launched

Honorary Professor Lin Pan-Sung from the Department of Design is the official tour-guide for the exhibition, introducing the historical stories of the works and cultural relics. President Wu Cheng-Chih, Dean of the College of Arts Liu Chien-Cheng, Director of the Department of Design Su Wen-Qing, and up to a hundred entrepreneurs and senior designers gathered to witness the important moments in the past century.
In view of the fact that “Taiwanology” is a prominent study in the current academic field, Professor Lin Pan-Sung took the lead in promoting and expanding the research of Taiwan Design, by raising NT$ 1 million to set up “Taiwan Design Research Award”. The main core is to encourage and explore local design resources and the uniqueness of historical development in Taiwan, enhance and to promote long-term research of Taiwan’s design academics.
Professor Lin Pan-Sung proclaim that NTNU has played an important role in the inspiration of modern art and design of education in Taiwan. Since Taihoku High School period, numerous excellent teachers such as Shiotsuki Toho, Mo Ta-Yuan, Lin Yu-Shan, Liao Wei-Lin, Wang Chien-Chu, Su Mao-Sheng, Wang Hsiu-Hsiung and more dedicated themselves in the education of design in NTNU which has influenced countless students over the past century. Truthfully aim that the veins and texture of the design will get clearer while laying a solid foundation for the next century through the Centennial Design Exhibition.
Date and Time: 7 Sept – 29 Sept (Weekdays 2-5pm; Weekends 9-5pm), 9/9-11 and Mondays are not available
Venue: Taiwan Design Corner
Organizer: Department of Design, NTNU
Hashtag: #DepartmentofDesignNTNU
Economic Corridor to Boost Regional Trade and Growth Through Laos
The Ministry of Public Works and Transport on Wednesday launched an initiative to improve transport, connectivity, climate resilience, and east-west regional trade across the north of the country.
Laos, Thailand and China to Construct New Railway Bridge for Freight
Thailand has been transporting more cargo to China by rail since the opening of the Laos-China railway. The shorter time required to carry products by rail has resulted in a rise in Thai exports to China.
MIMS Announces Strategic Collaboration with Syneos Health Communications to Enhance Digitally-Enabled Solutions
“This collaboration complements each company’s geographical footprint to ensure the voice of APAC is heard in any global assignment,” said Victor Wright, President, Medical Marketing Strategic Unit, MIMS. “By tapping into Syneos Health Communications’ expertise and capabilities, we can offer new solutions that enable clients to further drive their commercial success.”
For more than 50 years, MIMS has been a trusted medical knowledge source dedicated to empowering healthcare professionals. MIMS has deep and diverse expertise in the medical marketing space – from data-driven marketing and events management to scientific strategy and digital medication safety solutions. Today, MIMS is present in 16 markets across APAC and over two million healthcare professionals subscribe to its drug and resource portal, inclusive of both digital and print publications.
“This is an exciting chapter in our global growth strategy and strengthens our position as a leading multi-dimensional, full-service communications powerhouse,” said Ian Dorrian, President, Syneos Health Communications Europe. “Already operating in the US, South America, India and Europe, our collaboration with MIMS will advance our deep medical affairs, clinical and commercial deployment footprints in APAC by adding a variety of comprehensive regional communications disciplines.”
Syneos Health Communications is the only healthcare communications network that is part of a company on the frontlines of healthcare, with a clear view into the everyday complexities of life and health. As part of Syneos Health® (Nasdaq:SYNH), its agencies – consisting of leading brands and experts in advertising, branding, public relations, managed markets and medical communications – are engaged in every point of influence in health, providing real-world insight into markets and audiences in ways that no other partner could.
Hashtag: #MIMS #SyneosHealthCommunications #partnerships #AsiaPacific #medicalcommunications #healthcare #pharmaceuticalmarketing #healthcaremultichannel #medicalnews
About MIMS: Empowering Healthcare Communities to Improve Patient Outcomes
MIMS is Asia’s largest multi-channel provider of drug information, medical communications, events management and marketing services. Established in 1963, our work empowers healthcare professionals to improve patient outcomes by facilitating knowledge exchange and better decision- making. Today, MIMS is present in 16 markets across Asia Pacific with over two million healthcare professional subscribers to our drug & resource portal, digital and print publications.
Combining healthcare communications expertise with our established networks and presence in the Asian healthcare community, we enable clients to engage their stakeholders in meaningful dialogue through a range of medical and marketing communications services.
MIMS has offices in the following Asia markets:
Singapore (headquarters), Australia, China, Hong Kong SAR, Indonesia, India, Japan, Korea; Malaysia, Myanmar, New Zealand, Philippines, Taiwan, Thailand, UAE, Vietnam
Learn more at https://corporate.mims.com/ or follow us on
https://www.linkedin.com/company/mims-pte-ltd/
About Syneos Health Communications: At the Heart of Health
Syneos Health Communications is a purpose-built portfolio of innovative health-first, health-only advertising, branding, medical communications, market access and public relations agencies. We are fiercely focused on creating platforms that allow our customers to bring life-changing healthcare solutions to the world. We are an unrivaled community—powered by 29,000 clinical and commercial minds across Syneos Health®—that operates at the intersection of health, technology, and creativity. By harnessing data and behavioral sciences, we get to deeper, more actionable insights that drive behavior change.
Our agencies include Addison Whitney, Biosector 2, Cadent Medical Communications, Chamberlain Healthcare Public Relations, Chandler Chicco Agency, GSW, Litmus, Genicos and Spherico Managed Markets Communications. We work as scalable, collaborative teams that partner across disciplines and geographies to deliver integrated communications strategies that accelerate brand performance.
Learn more at syneoshealthcommunications.com or follow us on
https://www.linkedin.com/company/syneoshealthcommunications/
Medtronic Ranked One of 2022 Best Workplaces in Asia™
“Our people are our greatest strength, and we are glad that our employees feel proud to be part of Medtronic. This recognition means so much to us as it was based on the valuable feedback of our employees. Medtronic’s mission, created more than 60 years ago, highlights our commitment to recognize the personal worth of all employees. We celebrate our people who always go above and beyond and take great pride in their work,” said Neil Chalker, Vice President, Human Resources, Medtronic APAC.
According to Great Place to Work data, 88% of employees at the Best Workplaces in Asia on average reported having a positive employee experience. For the average global workforce, only 55% of workers report a similarly positive experience.
Being ranked amongst Asia’s top 5 best workplaces is the jewel in the crown for Medtronic. The company has also been certified as a Great Place to Work® organization across 13 APAC countries that it has presence in, including Australia, Bangladesh, India, Indonesia, Japan, Malaysia, New Zealand, Philippines, Singapore, South Korea, Sri Lanka, Thailand, Vietnam.
“At Medtronic, we believe in giving our employees a purpose, a voice and support to reach their full potential. I’m very proud that Medtronic has been ranked best workplace amongst Asia’s top MNCs and equally glad that our Singapore office has been certified as a Great Place to Work® organization for the third time in a row. This ranking is testament to how we are continuously engineering the extraordinary to bring about an inclusive and equitable culture in which all employees can reach their potential and maximize our collective impact to the patients we support,” said Jennifer Cho, Vice President & Managing Director, Medtronic Singapore & Malaysia.
“Congratulations to the Best Workplaces in Asia for putting the well-being of their employees first,” said Michael C. Bush, Global CEO of Great Place to Work. “During an incredibly challenging time for the region, these companies created equitable workplaces by providing flexibility and supporting their employees through strife. The Best Workplaces in Asia embody the mission of Great Place to Work and are indeed making work great For All.”
Hashtag: #Medtronic
The issuer is solely responsible for the content of this announcement.
2022 Taitung Blue Ocean Daily— Reinvigorating the 4 major sea leisure destinations to create oceanic life amidst our slow economy

April Yao, mayor of Taitung County, expressed that Taitung has the longest coastline in Taiwan with two pearls on the ocean: Green Island and Orchid Island, Jinzun Fishing Port, an international class surfing sanctuary, and a living lake connecting with the sea. With a spectacular environment, the Taitung County Government endeavors to develop a natural and real economy model to continuously invigorate the sea leisure bases destinations and also develop and promote water activities. The Blue Ocean Daily helps to promote and deepen the prolific leisure experiences in Taitung. As the Blue Ocean Daily goes international, it focuses on three core values: the promotion of ocean culture, regional revitalization and cultural exchange, as well as connecting Taitung with the world.
The four-week Blue Ocean Daily has 16 water leisure events to be experienced. The county government not only invited Kimokeo Kapahulehua (Unkle K), a world-class performer from Hawaii, but also introduced an Austronesian outrigger canoe to allow visitors to experience the daily ocean life in Taitung. The Blue Ocean Daily has also launched tour packages with local tour groups, these packages include 7 outrigger canoe trips, 4 SUP experience events, 4 canoe trips, and 1 minibike tour. During the gala, the tour begins at the sea floor, with exciting guided-tours during the day and star watching trips at night to present the charm of sea-land-air tours on the Green Island to visitors. In this event, exchanges between local academic groups and international organizations will be held. An international Austronesian maritime culture organization is also invited to lecture students at local schools about the core of indigenous culture and natural ecology. The event also promotes in-depth cultural exchanges between Hawaiian groups with local tribes/communities. As part of connecting Taitung to the world, the county government is eager to make experiencing daily life in the sea more diverse and profound.
Yu Ming-Hsun, Director of the Taitung County Tourism Department, emphasized how September 22 is a special day with historic significance: September 22 will be the day the legacy is continued and on the same day the Taitung County Government will hold the Oceanic Austronesian Culture Featuring Indigenous Tribal Experience in collaboration with the Kimokeo Foundation of Hawaii and local tribes. Participants will challenge long-distance sailing across the sea on outrigger canoes in Taiwan. The canoes will depart from Shan Yuan Beach and sail for about 30 km to the traditional waters of the Dulik tribe to recreate the traditional saluo: a visitation done with canoes. The tribes on the shore will respond with horns and receive the visitors from the sea in accordance with the Amis tradition, leaving all with good memories in this Blue Ocean Daily. The history of the Austronesian tribes visiting each other and maintaining friendship on outrigger canoes has exceeded three thousand years, with Taiwan as their home.
The Blue Ocean Daily will restore the art of celestial navigation in ancient times and continue to promote the unique charm of outrigger canoes and the magnificent seas well into the future.
For more information, please visit Taitung Blue Ocean Daily’s FB page: https://www.facebook.com/profile.php?id=100083162535238
Please sign up for the Ocean Fun Experience at the Taitung Fun Card website: https://www.ttfuncard.tw/zh-TW?tag=971644c7-72da-4505-a17b-51c4dacadc27
Hashtag: #TaitungCountyGovernment
Betters Medical Investment Holdings Limited to raise a maximum of approximately HK$427 million1 by way of Global Offering
· One of the leading microwave ablation (MWA) medical device developers and providers in the PRC for minimally invasive treatment of tumours. MWA medical devices are used for treatment of benign and malignant tumours including thyroid nodules, liver cancer, lung cancer and breast lumps.
· The Group ranked first among MWA medical device providers in the treatment for thyroid nodules and breast lumps in the PRC in terms of sales revenue and sales volume of MWA needles in 2021; The Group is the third largest MWA medical device provider in the PRC in terms of sales revenue in 2021.2
· The Group is the first company to have proprietary MWA medical devices specifically indicated for thyroid nodules successfully registered as Class III medical devices.2
· For the five months ended 31 May 2022, 259 hospitals in China procured products of the Group, among which, 150 were Grade IIIA hospitals.
· As at 13 September 2022 (the “Latest Practicable Date”), the Group possessed a total of 27 registered patents in China.
Financial Highlights
For the year ended 31 December | For the five months ended 31 May | ||||
(RMB’000) | 2019 | 2020 | 2021 | 2021(unaudited) | 2022 |
Revenue | 85,029 | 118,287 | 188,664 | 59,605 | 63,764 |
Gross Profit | 75,987 | 101,896 | 156,741 | 52,122 | 54,040 |
(Loss)/Profit before tax expense | (40,718) | 62,527 | 90,940 | 27,703 | 26,614 |
(Loss)/Profit for the year/period | (49,661) | 46,692 | 74,857 | 22,133 | 21,146 |
HONG KONG SAR – Media OutReach – 21 September 2022 – Betters Medical Investment Holdings Limited (“Betters Medical” or the “Company”, together with its subsidiaries, the “Group”, stock code: 6678.HK), one of the leading microwave ablation (MWA) medical device developers and providers in the PRC, announces the details of its plan to list on the Main Board of The Stock Exchange of Hong Kong Limited (“SEHK”) today.
A total of 248,000,000 shares (subject to the Over-allotment Option) will be offered under the Share Offer, of which 90%, or 223,200,000 shares (subject to reallocation and the Over-allotment Option), will be offered by way of International Placing; while the remaining 10%, or 24,800,000 Shares (subject to reallocation) will be offered under the Hong Kong Public Offer. The Offer Price per Offer Share is expected to be not less than HK$1.40 and not more than HK$1.72. The Hong Kong Public Offer will commence at 9:00 a.m. on 22 September 2022 (Thursday) and close at 12:00 noon on 27 September 2022 (Tuesday). The final offer price and allotment results are expected to be announced on 3 October 2022 (Monday). Dealings in shares of Betters Medical on the Main Board of the SEHK are expected to commence on 5 October 2022 (Wednesday).
Assuming an Offer Price of HK$1.56 per Offer Share (being the mid-point of the indicative price range of the Offer Price), the aggregated net proceeds from the Share Offer, after deducting related expenses and assuming the Over-allotment Option is not exercised, will be approximately HK$300.2 million. The Group intends to use these net proceeds for the following purposes: 1) approximately 41.0% for broadening and deepening product portfolio, upgrading medical licences and expanding R&D team; 2) approximately 38.0% for selectively pursuing strategic acquisitions, investment or synergistic business cooperation opportunities; 3) approximately 8.0% for expanding presence in foreign and emerging markets by setting up overseas offices; 4) approximately 3.0% for acquiring automated machineries and equipment to improve the automation level of production lines; and 5) approximately 10.0% for additional working capital and other general corporate purposes.
BOCI Asia Limited and Zhongtai International Capital Limited are the Joint Sponsors. BOCI Asia Limited, Zhongtai International Securities Limited, China Galaxy International Securities (Hong Kong) Co., Limited and Cinda International Capital Limited are the Joint Global Coordinators, Joint Bookrunners and Joint Lead Managers. Huatai Financial Holdings (Hong Kong) Limited, Eddid Securities and Futures Limited, China Everbright Securities (HK) Limited, Guosen Securities (HK) Capital Company Limited, China Industrial Securities International Capital Limited and Valuable Capital Limited are the Joint Bookrunners and Joint Lead Managers. ZMF Asset Management Limited are the Joint Lead Manager.
Business Overview
The Group is one of the leading MWA medical device developers and providers in the PRC for minimally invasive treatment of tumours. The proprietary MWA medical devices of the Group are used for treatment of benign and malignant tumours including thyroid nodules, liver cancer, lung cancer and breast lumps, which have experienced rising incidence rates in China. According to Frost & Sullivan, the Group is first company to have its proprietary MWA medical devices specifically indicated for thyroid nodules successfully registered as Class III medical devices. As at the Latest Practicable Date, the Group had obtained the Class III medical device registration certificate for its MWA medical devices specifically indicated for liver cancer and thyroid nodule.
According to Frost & Sullivan, the Group ranked first among MWA medical device providers in the treatment for thyroid nodules and breast lumps in the PRC in terms of sales revenue and sales volume of MWA needles in 2021; the Group is the third largest MWA medical device provider in the PRC in terms of sales revenue in 2021.
During the Track Record Period, all revenue of the Group was derived from China. Products of the Group are ultimately sold to hospitals for end consumption by their patients. These hospitals were mostly Grade II and Grade III hospitals across 22 provinces, municipalities and autonomous regions in China. For the five months ended 31 May 2022, 259 hospitals in China procured products of the Group, among which, 150 were Grade IIIA hospitals.
The Group experienced a strong growth in financial results during the Track Record Period. For the year ended 31 December 2019, 2020 and 2021, revenue of the Group was approximately RMB85.0 million, RMB118.3 million and RMB188.7 million respectively, which record a CAGR of 49.0%. The Group turned from a net loss of RMB49.7 million for FY2019 to a net profit of RMB46.7 million and RMB74.9 million for FY2020 and FY2021, respectively. For the five months ended 31 May 2022, revenue and net profit of the Group was RMB63.8 million and RMB21.1 million respectively.
Competitive Strengths
1. One of the leading MWA medical device developers and providers in the PRC for minimally invasive treatment of tumours in a fast-growing and underserved MWA medical device market in China
From 2016 to 2021, the market size of China’s tumour ablation industry in terms of hospital charge price has increased from RMB1.9 billion to RMB4.1 billion and is expected to reach RMB14.7 billion in 2026 with a CAGR of 30.6% from 2022 to 2026. MWA is the largest sector of tumour ablation therapy market in China, contributed to 57% of the overall ablation market. According to Frost & Sullivan, the Group ranked first among MWA medical device providers in the treatment for thyroid nodules and breast lumps in the PRC in terms of sales revenue and sales volume of MWA needles in 2021. MWA medical devices of the Group primarily target specialty areas with significant efficacy with MWA technology and with substantial market growth potential including both (i) benign tumours with a particular focus on thyroid nodules and breast lumps; and (ii) malignant tumours with particular focus on liver cancer and lung cancer.
2. Established a solid and strategically managed sales and distribution network
The Group have a solid and strategically managed sales and distribution network across China. For the five months ended 31 May 2022, products of the Group have been sold directly, through deliverers and on-sold by distributors to 259 hospitals across 22 provinces, municipalities and autonomous regions in China. With the network of deliverers and distributors, the number of hospitals in China purchasing products of the Group increased from 258 for FY2019 to 303 for FY2021, among which the number of Grade IIIA and Grade IIIB hospitals increased from 149 to 177. According to Frost & Sullivan, there are a total of 10 hospitals in Guangdong Province that are listed as the top 100 hospitals in the PRC issued by the Hospital Management Institute of Fudan University* (復旦大學醫院管理研究所) in 2020, and the Group have managed to sell the products to six of them during the Track Record Period.
3. Established relationship with market participants which greatly enhances R&D capabilities
The Group is the first company to have proprietary MWA medical devices specifically indicated for thyroid nodules registered as Class III medical devices, according to Frost & Sullivan. Also, the Group had obtained (i) one registration certificate for Class III medical devices and (ii) two registration certificates for Class II medical devices. Its products have wide application to different tumours including both (i) benign tumours with a particular focus on thyroid nodules and breast lumps; and (ii) malignant tumours with particular focus on liver cancer and lung cancer. As at the Latest Practicable Date, the Group possessed, as sole owner or co-owner, a total of 27 registered patents in China, and have made applications for 20 additional patents.
4. One of the leading players in the MWA medical device industry who add value to stakeholders in the value chain
MWA is one of the available treatment options of certain types of benign and malignant tumours that has the advantage of being safe, minimally invasive and easy to operate with a rapid recovery and low complication rate for patients. MWA treatments can also prevent a benign tumour from developing to a malignant tumour and therefore preventing cancer at early stage.
For hospitals, MWA medical devices of the Group provide them with a surgical alternative to conventional open surgery and chemotherapy for some of the patients who are suitable for undergoing MWA treatment. Patients undergoing MWA treatment also require less observation period and stay period (if any) post operation. Therefore, hospitals providing MWA treatment, thereby reducing the number of open surgery or chemotherapy patients, can reduce burden on hospital capacity; For medical practitioners, MWA medical devices of the Group provide them with a surgical alternative to tumour treatment for the patients. MWA treatment requires relatively short operation time and involves relatively low risk as compared to open surgery. In addition, MWA medical devices of the Group are currently covered by the national medical insurance in Guangdong Province and the reimbursement rate is up to 80% of the total fee for employee insurance and up to 60% of the total fee for rural insurance, which can further decrease the payers medical expenses reimbursement.
5. A visionary and experienced management team with proven track record
The Group has an experienced, dedicated and stable management team, with deep industry knowledge and management expertise that have contributed to our success so far. The Group is led by a management team who has rich working experience in medical companies. Senior management team of the Group includes members with background in accounting, R&D and merchandising. The Group believes that its leadership team, with their strong management talent, and the utilisation of its vast distribution networks and industry experience, will help the Group sustains an organic growth and future development.
BUSINESS STRATEGIES
1. Selectively pursue strategic acquisitions or investment
The Group plans to actively seek suitable opportunities for strategic acquisitions, investment or synergistic business cooperation to grow the business, expand product portfolio, enhance sales and distribution network and strengthen R&D capabilities to further consolidate market position. The Group believes there are ample opportunities, including companies that offer laser ablation products and technologies, companies that offer MWA products and technologies (including microbubble ultrasound cavitation enhanced MWA products and technologies), companies that focus on the development of AI and are in possession of the relevant products and technologies. Directors of the Group confirm that as at the Latest Practicable Date, they had not identified any specific acquisition target, formed any specific acquisition plan or entered into any agreement with potential target.
2. Broaden and deepen product portfolio, upgrade medical licences and expand R&D team
R&D staff of the Group will continue to broaden and deepen product portfolio, in a bid to strengthen the position in the MWA medical device market. The Group plans to expand the coverage of its Class III medical device registration certificates for its proprietary MWA medical devices specifically indicated for breast lumps, pulmonary nodules, varicose vein, bone tumours, uterine fibroid, prostate cancer and other diseases. The Group also plans to study, research on and develop MWA intelligence, as well as to launch new products in the underserved and fast growing MWA medical device market in the PRC.
3. Expand the presence in foreign and emerging markets by setting up overseas offices
The Group intends to tap into suitable overseas markets such as the U.S. and Europe that it believes are with good market growth potential by establishing overseas offices to implement its business development strategy and seek collaboration opportunities with local sales channels. The Group will conduct market research on the tumours ablation therapy markets in Europe and the U.S. and formulate a concrete overseas marketing plan in 2023; the Group intends to start cooperating with renowned overseas medical experts and professors to promote its brand and products in the overseas markets in the second half of 2023; expects to set up overseas office and recruit overseas sales and marketing staff for sales and after-sale services in the first quarter of 2024.
To promote brand name overseas, the Group will participate in prominent international medical conferences, such as China International Medical Equipment Fair (中國國際醫療器械博覽會), MEDICA and Florida International Medical Expo (FIME) to promote our products and build our brand reputation among influential KOLs and major medical associations in the MWA field of our targeted overseas markets.
4. Acquire automated machineries and equipment to improve the automation level of our production lines
To increase standardisation of production process and production efficiency, the Group plans to automate certain production steps by installing various types of automatic machineries and equipment in the Nanjing Plant 2 and the Suzhou Plant. The Group will provide training to its production staff on the operation of the new machineries and equipment and the automated production process. In addition, Directors believe that improved automation in the production process will enhance operational efficiency, strengthen capacity in producing highly standardised quality MWA medical devices, and increase the recognition of their proprietary MWA medical devices among medical practitioners.
Hashtag: #BettersMedical
About the Betters Medical Investment Holdings Limited
Betters Medical Investment Holdings Limited is one of the leading microwave ablation (MWA) medical device developers and providers in the PRC for minimally invasive treatment of tumours. Proprietary MWA medical devices of the Group are used for treatment of benign and malignant tumours including thyroid nodules, liver cancer, lung cancer and breast lumps, which have experienced rising incidence rates in China. According to Frost & Sullivan, the Group is the first company to have proprietary MWA medical devices specifically indicated for thyroid nodules successfully registered as Class III medical devices; ranked first among MWA medical device providers in the treatment for thyroid nodules and breast lumps in the PRC in terms of sales revenue and sales volume of MWA needles in 2021; the third largest MWA medical device provider in the PRC in terms of sales revenue in 2021.